• One Health
  • Pain Management
  • Oncology
  • Anesthesia
  • Geriatric & Palliative Medicine
  • Ophthalmology
  • Anatomic Pathology
  • Poultry Medicine
  • Infectious Diseases
  • Dermatology
  • Theriogenology
  • Nutrition
  • Animal Welfare
  • Radiology
  • Internal Medicine
  • Small Ruminant
  • Cardiology
  • Dentistry
  • Feline Medicine
  • Soft Tissue Surgery
  • Urology/Nephrology
  • Avian & Exotic
  • Preventive Medicine
  • Anesthesiology & Pain Management
  • Integrative & Holistic Medicine
  • Food Animals
  • Behavior
  • Zoo Medicine
  • Toxicology
  • Orthopedics
  • Emergency & Critical Care
  • Equine Medicine
  • Pharmacology
  • Pediatrics
  • Respiratory Medicine
  • Shelter Medicine
  • Parasitology
  • Clinical Pathology
  • Virtual Care
  • Rehabilitation
  • Epidemiology
  • Fish Medicine
  • Diabetes
  • Livestock
  • Endocrinology

Volition signs exclusive license and supply agreement with Heska

Article

The $28 million agreement will allow Volition to distribute the Nu.Q Vet Cancer Screening test worldwide.

ASDF/stock.adobe.com

ASDF/stock.adobe.com

VolitionRx Limited (Volition)—a multinational epigenetic company announced it signed an exclusive global supply and license agreement with Heska Corporation (Heska)—a global provider of advanced veterinary diagnostics. Through the new agreement, Heska will receive exclusive worldwide rights to sell Volition’s Nu.Q Vet Cancer Screening test. According to the release, in exchange, Volition will receive a $10 million upfront payment on signing and up to $18 million based on milestone achievements near/mid-term.1

"We are thrilled to announce this agreement with Heska, a company dedicated to developing the next generation of rapid, highly affordable, point-of-care diagnostics for companion animals," expressed Tom Butera, DVM, chief executive officer of Volition Veterinary Diagnostics Development LLC, in the release.1

"We estimate the total addressable market worldwide for cancer screening and monitoring in canines and felines to be approximately $11 billion and growing. As such, we want to make our Nu.Q Vet Cancer Screening Test as accessible as possible to veterinarians around the world, ensure cancer is detected earlier, and improve outcomes for pets and pet owners," he explained

According to the release, Volition’s Nu.Q Vet Cancer Screening test will operate on Heska’s propriety point of care platform Element i+ Immunodiagnostic Analyzer.1 With this agreement, veterinarians will be able to screen pets for some of the most common cancers while providing crucial information to clients.

"The accurate, affordable, fast, and noninvasive Nu.Q Vet Cancer Screening Test is exactly such an innovation and is a perfect addition to our Heska test menu, which we believe is now the most complete, differentiated, and cutting-edge point of care diagnostics solutions stack available for pet healthcare professionals and pet families,” said Kevin Wilson, Heska's chief executive officer, and president.

“With the new Heska Nu.Q Vet Cancer Screening Test millions of pets will have access to critical cancer screening and monitoring instantly, and at the point of care, to catch, treat and drive recovery from cancers earlier and with much better healthcare outcomes and peace of mind,” he continued, in the release.

Reference

Volition Signs Exclusive $28 million License and Supply Agreement with Heska Corporation to Distribute Nu.Q® Vet Cancer Screening Test at the Point of Care. News release. VolitionRx Limited. March 29, 2022. Accessed March 30, 2022. https://www.prnewswire.com/news-releases/volition-signs-exclusive-28-million-license-and-supply-agreement-with-heska-corporation-to-distribute-nuq-vet-cancer-screening-test-at-the-point-of-care-301512651.html

Related Videos
Innovators
Senior Bernese Mountain dog
© 2024 MJH Life Sciences

All rights reserved.